- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05022472
Project 2VIDA! COVID-19 Vaccine Intervention Delivery for Adults in Southern California (2VIDA!)
Project 2VIDA! SARS-CoV-2 Vaccine Intervention Delivery for Adults in Southern California
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
California
-
Chula Vista, California, United States, 91910
- San Ysidro Health Chula Vista
-
San Diego, California, United States, 92114
- Care View Health Center
-
San Diego, California, United States, 92114
- San Ysidro Health Care View Health Center
-
San Diego, California, United States, 92114
- San Ysidro Health Euclid
-
San Diego, California, United States, 92114
- San Ysidro Health King-Chavez Health Center
-
San Ysidro, California, United States, 92173
- San Ysidro Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- age 16 years or older
- identify as Latinx and/or AA
- biologically male or female
- be a resident of one of the six communities selected for this study (National City, Lincoln Park, Logan Heights, Valencia Park, Chula Vista or San Ysidro)
- literate in English or Spanish
- no known history of severe allergic reactions to any components of the vaccine
- no history of immune disease
- not be pregnant
- no plans to move from the area in the following 30 days
- able to provide voluntary informed consent
- able to provide complete contact information for themselves and two additional contact individuals (for follow-up 2nd vaccine shot)
Exclusion Criteria:
- under 16 years old
- pregnant women
- individuals unable to consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention
We will use a 2-armed randomized controlled trial (RCT) where Latino and AA adults >18 years or older from six participating communities and surrounding community health centers (CHC) will be assigned to the 2 VIDA! intervention (n=3 CHC; N=500 participants) or to the control site (e.g., standard of care) (n=3 CHC; N=500 participants).
The two major components of the 2VIDA!
intervention are: COVID-19 Individual Awareness and Education, COVID-19 Community Outreach and Health Promotion, COVID-19 Individual Health Education and Linkages to Medical and Supportive Services, and pop-up vaccination stations in Latino and AA communities.
|
The 2VIDA! working group has developed culturally competent COVID-19 educational and outreach materials (available printed and electronically) in English and Spanish that are written at the 8th grade level (the average reading level of adults in the United States) that peer-health educators will distributed to community members during their visits to the participating SYH community centers, door-to-door, local supermarkets, and CBO's in the selected communities.
These materials have general information on COVID-19 as well as educational information and resources regarding COVID-19 prevention, symptoms, testing, contact tracing, COVID-19 vaccine (how it works, technology used, administration [2-dose series and importance of vaccine completion]), safety concerns, benefits, dispelling common misconceptions and misinformation, and other topics identified based on community needs.
This information will be updated monthly to ensure the most up to date information.
Peer-health educators will work with local CBO's and facilitate a combination of live broadcast sessions, pre-recorded webinars, social media posts, and other outreach activities in English and Spanish reaching community members with information on the above COVID-19 related topics as well as other identified needs such as what to do if a family member is infected and where you can get the COVID-19 vaccine.
The goal is to reach 10,000 viewers (per session) in the various social media platforms in the three randomly selected communities.
SYHealth will establish a COVID-19 Resource Center within the participating health centers in the three randomly selected communities (intervention sites only) providing individual COVID-19 related health education and linkages to medical and supportive services for patients and community members in need of additional education and support regarding COVID-19 disease and COVID-19 vaccine.
We will offer the COVID-19 vaccine at the participating SYHealth community health centers and pop-up vaccination stations that will be set-up in these communities (intervention sites) as part of the interventions efforts to increase access and uptake of the COVID-19 vaccine.
We have identified various open spaces (e.g., public parks) in these communities to set-up the vaccination stations.
Additionally, data will be collected to assess individual, social, and contextual factors related to access, acceptance, and uptake of the COVID-19 vaccine.The survey will last approximately 10-15 minutes and will be self-administered in both English and Spanish.
Following the survey participants will be offered the COVID-19 vaccine and will be made an automatic appointment for the 2nd dose (4-week follow-up) and will be asked to complete a 5 min survey during the follow-up visit.
|
|
No Intervention: Standard of care
The standard of care for vaccine delivery at the control sites.
This includes individuals who make an appointment on their own or receive the vaccine at a health center and may receive information about the vaccine from their primary healthcare provider.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Vaccine Hesitancy
Time Frame: Baseline (current), and follow-up (4-weeks)
|
Based on the definition of the Strategic Advisory Group of Experts (SAGE) Working Group on Vaccine Hesitancy (WG), hesitancy refers to "delay in acceptance or refusal of vaccination despite availability of vaccination services.
Vaccine hesitancy is complex and context specific, varying across time, place and vaccines.
It is influenced by factors such as complacency, convenience and confidence."
|
Baseline (current), and follow-up (4-weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Health Literacy
Time Frame: Baseline and follow-up (4-weeks)
|
Assessment of ease/difficulty in finding information on symptoms, finding out what to do if infected, understand what authorities say, judge reliability of information, follow recommendations, decide on prevention behaviors.
(Adapted from the WHO COVID-19 Survey Tool and Guidance).
|
Baseline and follow-up (4-weeks)
|
|
Change in COVID-19 Risk Perception (Probability and Severity)
Time Frame: Baseline and follow-up (4-weeks)
|
Self-assessed probability and susceptibility to of contracting COVID-19 and self-assessed severity in case of contracting COVID-19.
(Adapted from the WHO COVID-19 Survey Tool and Guidance).
|
Baseline and follow-up (4-weeks)
|
|
Change in Preparedness and Perceived Self-efficacy
Time Frame: Baseline and follow-up (4-weeks)
|
Self-assessed COVID-19 self-protection and avoidance ability.
(Adapted from the WHO COVID-19 Survey Tool and Guidance).
|
Baseline and follow-up (4-weeks)
|
|
Access to Health Care and Utilization
Time Frame: Baseline (current)
|
Type of insurance was assessed.
(Adapted from the National Health Interview Survey 2020)
|
Baseline (current)
|
|
Health History
Time Frame: Baseline
|
History of having medical conditions that could exacerbate COVID-19 infection including: type 1 and type 2 diabetes mellitus, hypertension, heart conditions (e.g., coronary artery disease), obesity (e.g., body mass index of 30kg/m2 or higher but <40km/m2), severe obesity (e.g., BMI >40 kg/m2), asthma, chronic obstructive pulmonary disease (COPD), smoking. "Ever told by a medical provider they had a chronic illness" |
Baseline
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Affect
Time Frame: Baseline and follow-up (4-weeks)
|
Affect related to COVID-19 including: close, spreading, constant, fear-inducing, media hyped, helpless, stressful, etc. (Adapted from the WHO COVID-19 Survey Tool and Guidance). From "Close to me" (0) to "Far away from me" (7) From "Spreading slowly" (0) to "Spreading fast" (7) From "Something I think about all the time" (0) to "Something I almost never think about" (7) From "Fear-inducing" (0) to "Not fear-inducing" (7) From "Media hyped" (0) "Not media hyped" (7) From "Something that makes me feel helpless" (0) to "Something I am able to combat with my own action" (7) From "Stressful" (0) to "Not stressful" (7) "Please drag and drop the slider to the statements below that best represents how you feel. There are no right or wrong answers. COVID-19 to me feels:" |
Baseline and follow-up (4-weeks)
|
|
Use of Sources of Information
Time Frame: Baseline and follow-up (4-weeks)
|
Use of information sources including television, newspaper, health workers, social media, radio, health department, Centers for Disease Control and Prevention (CDC), hotlines, official websites, and celebrities. (Adapted from the WHO COVID-19 Survey Tool and Guidance). "How often do you use the following sources for information about COVID-19?" |
Baseline and follow-up (4-weeks)
|
|
Trust in Sources of Information
Time Frame: Baseline and follow-up (4-weeks)
|
Trust in information sources including television, newspaper, health workers, social media, radio, health department, CDC, hotlines, official websites, and celebrities. (Adapted from the WHO COVID-19 Survey Tool and Guidance). "How much do you trust information about COVID-19 from the following sources?" |
Baseline and follow-up (4-weeks)
|
|
Frequency of Information
Time Frame: Baseline and follow-up (4-weeks)
|
Frequency in information.
(Adapted from the WHO COVID-19 Survey Tool and Guidance).
|
Baseline and follow-up (4-weeks)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Argentina E Servin, MD,MPH, UC San Diego
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 210630S
- 1R01MD016872-01 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitatsspital ZurichEnrolling by invitation
-
Alexandria UniversityCompleted
-
Erasmus Medical CenterUniversity Medical Center Groningen; Academisch Medisch Centrum - Universiteit... and other collaboratorsRecruiting
Clinical Trials on COVID-19 Individual Awareness and Education.
-
University of RochesterEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
Xavier University of Louisiana.CompletedCovid19 | Vaccine Hesitancy | Vaccine RefusalUnited States
-
University of California, San DiegoNational Institute on Drug Abuse (NIDA)Completed
-
Kilis 7 Aralik UniversityCompleted
-
University of California, San FranciscoNational Institute on Minority Health and Health Disparities (NIMHD); Duke...CompletedEducational ActivitiesUnited States
-
University of California, San FranciscoNational Institute of Allergy and Infectious Diseases (NIAID); Duke University and other collaboratorsTerminatedVaccine Hesitancy | Covid-19 VaccineUnited States
-
AstraZenecaCompleted
-
Duke UniversityNorth Carolina Department of Health and Human ServicesCompleted
-
University of Colorado, DenverNational Heart, Lung, and Blood Institute (NHLBI)RecruitingHypertension | Diabetes | Mental HealthUnited States
-
University of Missouri, Kansas CityNational Institute on Minority Health and Health Disparities (NIMHD)Active, not recruitingCOVID-19 Testing BehaviorsUnited States